Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 24, 2014 17:21 ET | Source: BioMarin Pharmaceutical Inc.

FDA Receives Paragraph IV Notice Letter for KUVAN(R) (sapropterin dihydrochloride) Tablets

SAN RAFAEL, Calif., Sept. 24, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that a Paragraph IV Certification Notice Letter was submitted to the US Food and Drug...
September 23, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Attend Upcoming Investor Conferences

- Jefferies Gene Therapy Summit on September 30 in Boston - Leerink Partners Rare Disease Roundtable on October 1 in New York SAN RAFAEL, Calif., Sept. 23, 2014 (GLOBE NEWSWIRE) -- BioMarin...
September 15, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Named by CenterWatch as One of the Fastest Developers of Medicines

SAN RAFAEL, Calif., Sept. 15, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that CenterWatch, a leading source for global clinical trial information, has named it...
September 10, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Attend Upcoming Investor Conferences in London

- J.P. Morgan Annual U.S. All Stars Conference in London on September 16 - Bank of America Merrill Lynch Global Healthcare Conference in London on September 17 SAN RAFAEL, Calif., Sept. 10, 2014...
August 19, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Present at Upcoming Investor Conferences

- Baird 2014 Healthcare Conference on September 3 - Citi Annual Biotech Conference on September 4 - Morgan Stanley Global Healthcare Conference on September 9 SAN RAFAEL, Calif., Aug. 19,...
July 30, 2014 16:01 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Sells Priority Review Voucher for $67.5 Million

SAN RAFAEL, Calif., July 30, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it has sold the Rare Pediatric Disease Priority Review Voucher (PRV) it obtained...
July 30, 2014 16:01 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces Second Quarter 2014 Financial Results

- VIMIZIM® Sales Top $14 million in First Full Quarter of Sales - Full Year Total BioMarin Revenue Guidance Increased Financial Highlights ($ in millions, except per share data,...
July 23, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

Sarah Cannon Research UK and BioMarin Collaborate on EMBRACA Clinical Study in Hereditary Breast Cancer With BRCA Mutation

SAN RAFAEL, Calif., July 23, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Sarah Cannon Research UK today announced a collaboration to enroll patients in an ongoing Phase 3...
July 09, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Host Second Quarter 2014 Financial Results Conference Call and Webcast on Wednesday, July 30 at 4:30pm ET

SAN RAFAEL, Calif., July 9, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today...
June 10, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Present at the Wells Fargo Healthcare Conference on June 17th

SAN RAFAEL, Calif., June 10, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today...